Literature DB >> 23104922

PA28γ is a novel corepressor of HTLV-1 replication and controls viral latency.

Nga Ling Ko1, John M Taylor, Marcia Bellon, Xue Tao Bai, Sergey P Shevtsov, Miroslav Dundr, Christophe Nicot.   

Abstract

UNLABELLED: The establishment of a latent reservoir by human tumor viruses is a vital step in initiating cellular transformation and represents a major shortcoming to current therapeutic strategies and the ability to eradicate virus-infected cells. Human T-cell leukemia virus type 1 (HTLV-1) establishes a lifelong infection and is linked to adult T-cell leukemia lymphoma (ATLL). Here, we demonstrate that HTLV-1 p30 recruits the cellular proteasome activator PA28γ onto the viral tax/rex mRNA to prevent its nuclear export and suppress virus replication. Interaction of p30 with a PA28γ retaining fully functional proteasome activity is required for p30's ability to repress HTLV-1. Consistently, HTLV-1 molecular clones replicate better and produce more virus particles in PA28γ-deficient cells. These results define a unique and novel role for the cellular factor PA28γ in the control of nuclear RNA trafficking and HTLV-1–induced latency. Importantly, knockdown of PA28γ expression in ATLL cells latently infected with HTLV-1 reactivates expression of viral tax/rex RNA and the Tax protein. Because Tax is the most immunogenic viral antigen and triggers strong CTL responses, our results suggest that PA28γ-targeted therapy may reactivate virus expression from latently infected cells and allow their eradication from the host. KEY POINTS: PA28γ acts as a co-repressor of HTLV-1 p30 to suppress virus replication and is required for the maintenance of viral latency. HTLV-1 has evolved a unique function mediated by its posttranscriptional repressor p30, which is not found in HTLV-2.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23104922      PMCID: PMC3563364          DOI: 10.1182/blood-2012-03-420414

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

Review 1.  Molecular dissection of the 11S REG (PA28) proteasome activators.

Authors:  J Li; M Rechsteiner
Journal:  Biochimie       Date:  2001 Mar-Apr       Impact factor: 4.079

Review 2.  Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.

Authors:  T Pierson; J McArthur; R F Siliciano
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Immune defects in 28-kDa proteasome activator gamma-deficient mice.

Authors:  Lance F Barton; Herbert A Runnels; Todd D Schell; Yunjung Cho; Reta Gibbons; Satvir S Tevethia; George S Deepe; John J Monaco
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

4.  Human T-lymphotropic type 1 virus p30 inhibits homologous recombination and favors unfaithful DNA repair.

Authors:  Hicham H Baydoun; Joanna Pancewicz; Christophe Nicot
Journal:  Blood       Date:  2011-03-22       Impact factor: 22.113

5.  Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease.

Authors:  M Yoshida; M Seiki; K Yamaguchi; K Takatsuki
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.

Authors:  M Yoshida; I Miyoshi; Y Hinuma
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

7.  Purification procedures determine the proteasome activation properties of REG gamma (PA28 gamma).

Authors:  Xiaolin Gao; Jun Li; Gregory Pratt; Sherwin Wilk; Martin Rechsteiner
Journal:  Arch Biochem Biophys       Date:  2004-05-15       Impact factor: 4.013

8.  HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication.

Authors:  Christophe Nicot; Miroslav Dundr; Julie M Johnson; Jake R Fullen; Norma Alonzo; Risaku Fukumoto; Gerald L Princler; David Derse; Tom Misteli; Genoveffa Franchini
Journal:  Nat Med       Date:  2004-01-18       Impact factor: 53.440

9.  Repression of human T-cell leukemia virus type 1 and type 2 replication by a viral mRNA-encoded posttranscriptional regulator.

Authors:  Ihab Younis; Lyne Khair; Miroslav Dundr; Michael D Lairmore; Genoveffa Franchini; Patrick L Green
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  13 in total

1.  miR-28-3p is a cellular restriction factor that inhibits human T cell leukemia virus, type 1 (HTLV-1) replication and virus infection.

Authors:  Xue Tao Bai; Christophe Nicot
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

2.  Multiple Pathways Control the Reactivation of Telomerase in HTLV-I-Associated Leukemia.

Authors:  Marcia Bellon; Christophe Nicot
Journal:  Int J Cancer Oncol       Date:  2015-06-02

3.  STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of HTLV-I-Transformed and ATL Cells.

Authors:  Ramona Moles; Marcia Bellon; Christophe Nicot
Journal:  Neoplasia       Date:  2015-05       Impact factor: 5.715

Review 4.  Tumor Suppressor Inactivation in the Pathogenesis of Adult T-Cell Leukemia.

Authors:  Christophe Nicot
Journal:  J Oncol       Date:  2015-06-10       Impact factor: 4.375

5.  Tax impairs DNA replication forks and increases DNA breaks in specific oncogenic genome regions.

Authors:  Hassiba Chaib-Mezrag; Delphine Lemaçon; Hélène Fontaine; Marcia Bellon; Xue Tao Bai; Marjorie Drac; Arnaud Coquelle; Christophe Nicot
Journal:  Mol Cancer       Date:  2014-09-04       Impact factor: 27.401

6.  NOTCH1 Activation Depletes the Pool of Side Population Stem Cells in ATL.

Authors:  Xue Tao Bai; Chien-Hung Yeh; Christophe Nicot
Journal:  J Cancer Sci       Date:  2017-06-14

7.  Proteasome activator PA28γ-dependent degradation of coronavirus disease (COVID-19) nucleocapsid protein.

Authors:  Haiyang Zhang; Jialu Tu; Chulei Cao; Ting Yang; Liangcai Gao
Journal:  Biochem Biophys Res Commun       Date:  2020-06-16       Impact factor: 3.575

Review 8.  The need to accessorize: molecular roles of HTLV-1 p30 and HTLV-2 p28 accessory proteins in the viral life cycle.

Authors:  Rajaneesh Anupam; Rami Doueiri; Patrick L Green
Journal:  Front Microbiol       Date:  2013-09-17       Impact factor: 5.640

9.  Increased proteasome activator 28 gamma (PA28γ) levels are unspecific but correlate with disease activity in rheumatoid arthritis.

Authors:  Melanie Gruner; Anja Moncsek; Stefan Rödiger; Dagmar Kühnhardt; Eugen Feist; Ralf Stohwasser
Journal:  BMC Musculoskelet Disord       Date:  2014-12-08       Impact factor: 2.362

Review 10.  PA28γ, an Accomplice to Malignant Cancer.

Authors:  Kexin Lei; Hetian Bai; Silu Sun; Chuan Xin; Jing Li; Qianming Chen
Journal:  Front Oncol       Date:  2020-10-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.